For procurement managers and R&D scientists in the pharmaceutical industry, sourcing high-quality intermediates is paramount to the success of drug development and manufacturing. (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol (CAS: 1374639-77-6) is a critical building block, particularly recognized for its role in the synthesis of Ribociclib, a vital medication for treating certain types of breast cancer. As a discerning buyer, understanding where and how to procure this essential compound can significantly impact your project's timeline and budget.

When searching for a reliable supplier of (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol, key considerations include product purity, consistency, and the manufacturer's adherence to quality standards. A minimum assay of 98.0% is generally expected for pharmaceutical intermediates to ensure the efficacy and safety of the final active pharmaceutical ingredient (API). Manufacturers located in China are often sought after due to competitive pricing and robust chemical manufacturing infrastructure. It is crucial to engage with suppliers who can provide comprehensive documentation, such as Certificates of Analysis (COA) and Material Safety Data Sheets (MSDS), alongside technical support.

For companies looking to buy (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol, it is advisable to seek out manufacturers with a proven track record in producing pharmaceutical intermediates. These suppliers typically offer detailed specifications, including molecular formula (C12H14ClN3O) and molecular weight (251.712), and can provide information on physical properties like appearance (typically a white crystalline powder) and storage recommendations. The price of this intermediate can vary based on quantity, purity, and market demand, making it essential to obtain quotes from multiple reputable manufacturers to ensure the best value.

Understanding the application of (2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanol as a Ribociclib intermediate underscores its importance in the oncology sector. Reliable sourcing of this compound directly influences the production efficiency and cost-effectiveness of Ribociclib. By partnering with experienced manufacturers, pharmaceutical companies can secure a stable supply chain, mitigate risks, and ultimately bring critical treatments to patients more effectively. For those seeking a dependable source for this key pharmaceutical intermediate, exploring leading chemical manufacturers in China is a strategic first step.